Research progress in clinical application of a novel calcineurin inhibitor:voclosporin
Voclosporin,an analogue of cyclosporine A,is an oral novel calcineurin inhibitor for autoimmune diseases such as plaque psoriasis,non-infectious uveitis and prevention of renal transplant rejection.Based on positive results from two pivotal phase Ⅱ and Ⅲ clinical trials,voclosporin was aproved by FDA in January 2021 for adult patients with active lupus nephritis in combination with a standrand treatment regimen.Recently,voclosporin has been explored for kidney transplant recipients with corona virus disease 2019(COVID-19).This article summarized the mechanism of action,pharmacokinetics and pharmacodynamics,dosage,co-administration and in-disease application of voclosporin in clinical treatment.
NETL
NSTL
万方数据
